Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Erland Erdmann

Showing results (21-30 of 138) with videos related to

Pageof 14
Sort By:
Herz|June 24, 2008
[Diabetes mellitus and heart failure: epidemiology and therapy]Roman Pfister, Erland Erdmann
MMW Fortschritte Der Medizin|February 2, 2008
[Uncertainly after publications on glitazones. Elevated myocardial infarction risk is not a class effect]Erland Erdmann, Werner A Scherbaum
European Heart Journal|January 3, 2008
Weighing up the cardiovascular benefits of thiazolidinedione therapy: the impact of increased risk of heart failureErland Erdmann, Robert G Wilcox
Plos One|December 29, 2010
Informed consent prior to coronary angiography in a real world scenario: what do patients remember?Aslihan Eran, Erland Erdmann, Fikret Er
Current Cardiology Reviews|August 3, 2010
Thiazolidinediones and cardiovascular risk - a question of balanceErland Erdmann, Bernard Charbonnel, Robert Wilcox
Pharmazie in Unserer Zeit|September 7, 2010
[PDE5 inhibitors in the treatment of pulmonary hypertension]Daniel Dumitrescu, Erland Erdmann, Stephan Rosenkranz
Journal of Diabetes|October 7, 2010
Pioglitazone and the risk of cardiovascular events in patients with Type 2 diabetes receiving concomitant treatment with nitrates, renin-angiotensin system blockers, or insulin: results from the PROactive study (PROactive 20)Erland Erdmann, Robert Spanheimer, Bernard Charbonnel, et al.
Deutsche Medizinische Wochenschrift (1946)|May 21, 2008
[Detached point of a thin lumen thorax drainage tube in the right lung]Fikret Er, Evren Caglayan, Erland Erdmann
American Heart Journal|March 29, 2008
Effects of pioglitazone on major adverse cardiovascular events in high-risk patients with type 2 diabetes: results from PROspective pioglitAzone Clinical Trial In macro Vascular Events (PROactive 10)Robert Wilcox, Stuart Kupfer, Erland Erdmann, et al.
Medizinische Klinik (Munich, Germany : 1983)|August 19, 2007
[Novel indications for phosphodiesterase type 5 inhibitors]Stephan Rosenkranz, Evren Caglayan, Erland Erdmann
Pageof 14

Showing results (21-30 of 138) with videos related to

Sort By:
Pageof 14
Herz|June 24, 2008
[Diabetes mellitus and heart failure: epidemiology and therapy]Roman Pfister, Erland Erdmann
MMW Fortschritte Der Medizin|February 2, 2008
[Uncertainly after publications on glitazones. Elevated myocardial infarction risk is not a class effect]Erland Erdmann, Werner A Scherbaum
European Heart Journal|January 3, 2008
Weighing up the cardiovascular benefits of thiazolidinedione therapy: the impact of increased risk of heart failureErland Erdmann, Robert G Wilcox
Plos One|December 29, 2010
Informed consent prior to coronary angiography in a real world scenario: what do patients remember?Aslihan Eran, Erland Erdmann, Fikret Er
Current Cardiology Reviews|August 3, 2010
Thiazolidinediones and cardiovascular risk - a question of balanceErland Erdmann, Bernard Charbonnel, Robert Wilcox
Pharmazie in Unserer Zeit|September 7, 2010
[PDE5 inhibitors in the treatment of pulmonary hypertension]Daniel Dumitrescu, Erland Erdmann, Stephan Rosenkranz
Journal of Diabetes|October 7, 2010
Pioglitazone and the risk of cardiovascular events in patients with Type 2 diabetes receiving concomitant treatment with nitrates, renin-angiotensin system blockers, or insulin: results from the PROactive study (PROactive 20)Erland Erdmann, Robert Spanheimer, Bernard Charbonnel, et al.
Deutsche Medizinische Wochenschrift (1946)|May 21, 2008
[Detached point of a thin lumen thorax drainage tube in the right lung]Fikret Er, Evren Caglayan, Erland Erdmann
American Heart Journal|March 29, 2008
Effects of pioglitazone on major adverse cardiovascular events in high-risk patients with type 2 diabetes: results from PROspective pioglitAzone Clinical Trial In macro Vascular Events (PROactive 10)Robert Wilcox, Stuart Kupfer, Erland Erdmann, et al.
Medizinische Klinik (Munich, Germany : 1983)|August 19, 2007
[Novel indications for phosphodiesterase type 5 inhibitors]Stephan Rosenkranz, Evren Caglayan, Erland Erdmann
Pageof 14